Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Genetics Focus::Myeloid

Cancer Genetics has introduced Focus::Myeloid, a comprehensive next-generation sequencing-based panel for the diagnosis, prognosis, and clinical management of myeloid cancer patients, including those with acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms. Utilizing Illumina NGS, the panel assesses 54 clinically relevant genes. Sanger sequencing is performed to assess abnormalities in several additional genes to provide a precise evaluation of the genetic profile of each patient's cancer, the company said. Focus::Myeloid is performed in CGI's CLIA certified lab, and is available as an individual test and as part of the company's complete programs for AML, MDS, and MPN, which offer a comprehensive assessment of the molecular genetics of the cancer along with pathology and morphological information.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.